Species |
Mouse |
Protein Construction |
IGFBP-7 (Ser26-Leu281)_x000D_ Accession # Q61581 |
hFc |
N-term |
C-term |
|
Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
Endotoxin Level |
Less than 1EU per μg by the LAL method. |
Biological Activity |
IGFBP-7 hFc Chimera, Mouse captured on CM5 Chip via Protein A can bind Human CD93, His Tag in SPR assay (Biacore T200). Test result was comparable to standard batch. |
Expression System |
HEK293 |
Theoretical Molecular Weight |
53.03 kDa |
Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 55-70 kDa based on Bis-Tris PAGE result. |
Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Target Background |
IGFBP-7, also known as Mac25/Angiomodulin (AGM), GFBP-rp1, tumor-derived adhesion factor (TAF) and prostacyclin-stimulating factor (PSF), is a secreted protein that contains three protein domain modules. Human IGFBP-rp1 cDNA encodes 282 amino acid (aa) residue precursor protein with a putative 26 aa signal peptide. IGFBP-7 binds IGF-I and IGF-II with a relatively low affinity. Stimulates prostacyclin (PGI2) production. Stimulates cell adhesion. |
Synonyms |
IGFBP-7; IBP7; AGM; FSTL2; IGFBP-7v; IGFBPRP1; MAC25; PSF; RAMSVPS; TAF |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.